Cited by 118Obstructive Sleep Apnea ResearchHormonal and reproductive studiesMenopause: Health Impacts and Treatments

Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo‐controlled trial

Hoyos, Camilla M., Killick, Roo, Yee, Brendon J., Grunstein, Ronald R., Liu, Peter Y.·2012·Clinical Endocrinology

Abstract

Summary: Study objectives: High doses of short‐term testosterone have been shown to acutely worsen sleep‐disordered breathing in men with obstructive sleep apnoea (OSA). The effects of lower, near‐conventional doses of testosterone in obese men with OSA may differ over the longer term but have not been systematically studied. We assessed sleep and breathing effects of near‐conventional testosterone treatment as an adjunct to weight loss in obese men with severe OSA. Design: An 18‐week randomized, double‐blind, placebo‐controlled, parallel group trial in 67 men. Interventions: All subjects were placed on a hypocaloric diet and then received intramuscular injections of 1000 mg testosterone undecanoate or placebo at 0, 6 and 12 weeks. Measurements and Results: Sleep and breathing were measured by nocturnal polysomnography at 0, 7 and 18 weeks. Testosterone, compared to placebo, worsened the oxygen desaturation index (ODI) by 10·3 events/h (95%CI, 0·8–19·8 events/h; P = 0·03) and nocturnal hypoxaemia (sleep time with oxygen saturation <90%, SpO 2 T90%) by 6·1% (95%CI, 1·5–10·6; P = 0·01) at 7 weeks. Testosterone therapy did not alter ODI (4·5, −5·4 to 14·4 events/h; P = 0·36) or SpO 2 T90% at 18 weeks (2·9, −1·9–7·7%; P = 0·23) compared to placebo. The testosterone treatment effects on ODI and SpO 2 T90% were not influenced by baseline testosterone concentrations (testosterone by treatment interactions, all P > 0·35). Blood testosterone concentrations did not correlate with ODI or SpO 2 T90% (all P > 0·19). Conclusions: Testosterone therapy in obese men with severe OSA mildly worsens sleep‐disordered breathing in a time‐limited manner, irrespective of initial testosterone concentrations. This time‐dependency was not related to testosterone concentrations. Trial Registration: www.anzctr.org.au Identifier: ACTRN1260‐6000404527.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2012.04413.x

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recent, preliminary RCT failed to find additive effects of dietary restriction and testosterone therapy on weight loss.

    “a recent, preliminary RCT failed to find additive effects of dietary restriction and testosterone therapy on weight loss.112”
  • In men with moderate-severe OSA, testosterone treatment significantly increased sleep-disordered breathing by a moderate amount (10 events/hour) at week 7 but not at week 18.

    “Testosterone treatment significantly increased sleep-disordered breathing by a moderate amount (10 events/hour) at week 7 (one week after the second injection of testosterone undecanoate), but not at week 18.”

    From Sleep, testosterone and cortisol balance, and ageing men (2022) · cites this paper as [129]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hoyos, C. M., Killick, R., Yee, B. J., Grunstein, R. R., & Liu, P. Y.
Affiliations
The University of Sydney (AU)
Corresponding author
Liu, Peter Y.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2012-09-11
Volume
77
Issue
4
Pages
599-607
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2027870056
Cited by
118
References
36
Citations by year
2026: 4 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 11 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 15 · 2014: 12 · 2013: 7 · 2012: 3
FWCI
7.93
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Health and Medical Research Council
  • National Medical Research Council
Topics
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
testosterone replacement therapy, testosterone undecanoate, obstructive sleep apnea, obesity, sleep-disordered breathing, nocturnal hypoxemia, oxygen desaturation index, hypocaloric diet, weight loss, men, testosterone levels, time-dependent effects, nocturnal polysomnography
MeSH terms
Double-Blind Method, Humans, Male, Middle Aged, Obesity, Respiration, Sleep, Testosterone, Sleep Apnea, Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review